Back to Search
Start Over
Alemtuzumab improves quality-of-life outcomes compared with subcutaneous interferon beta-1a in patients with active relapsing-remitting multiple sclerosis
- Source :
- Multiple sclerosis (Houndmills, Basingstoke, England). 23(10)
- Publication Year :
- 2016
-
Abstract
- Background: Alemtuzumab was superior on clinical and magnetic resonance imaging (MRI) outcomes versus subcutaneous interferon beta-1a in phase 3 trials in patients with relapsing-remitting multiple sclerosis. Objective: To examine quality-of-life (QoL) outcomes in the alemtuzumab phase 3 trials. Methods: Patients who were treatment naive (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis I [CARE-MS I]) or had an inadequate response to prior therapy (CARE-MS II) received annual courses of alemtuzumab 12 mg/day at baseline (5 days) and Month 12 (3 days) or subcutaneous interferon beta-1a 44 µg three times/week. QoL was measured every 6 or 12 months using Functional Assessment of Multiple Sclerosis (FAMS), European Quality of Life-5 Dimensions (EQ-5D) and its visual analog scale (EQ-VAS), and 36-Item Short-Form Survey (SF-36). Results: Statistically significant improvements from baseline with alemtuzumab were observed on all three QoL instruments at the earliest post-baseline assessment and sustained through Year 2. Statistically significant greater QoL improvements over subcutaneous interferon beta-1a were seen at all time points in CARE-MS II with FAMS, EQ-VAS and SF-36 physical component summary, and in CARE-MS I with FAMS. Conclusion: Patients treated with alemtuzumab had improvements in physical, mental, and emotional QoL regardless of treatment history. Improvements were significantly greater with alemtuzumab versus subcutaneous interferon beta-1a on both disease-specific and general measures of QoL.
- Subjects :
- Adult
Male
medicine.medical_specialty
Visual analogue scale
03 medical and health sciences
0302 clinical medicine
Multiple Sclerosis, Relapsing-Remitting
Quality of life
Internal medicine
medicine
Humans
Immunologic Factors
In patient
030212 general & internal medicine
Alemtuzumab
medicine.diagnostic_test
business.industry
Multiple sclerosis
Interferon beta-1a
Magnetic resonance imaging
Middle Aged
medicine.disease
Treatment Outcome
Neurology
Relapsing remitting
Physical therapy
Quality of Life
Female
Neurology (clinical)
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 14770970
- Volume :
- 23
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Multiple sclerosis (Houndmills, Basingstoke, England)
- Accession number :
- edsair.doi.dedup.....6f7e64864492c34121dc529de4668382